Randomised controlled trial to evaluate tolerance, intake and safety of a new high-energy high-protein oral nutritional supplement in elderly subjects in need of oral nutritional support.

1. Male/female subjects ≥ 65 years of age;

2. Subject is in need of oral nutritional support of ≥ 300 kcal/day;

3. Subject is expected to require oral nutritional support for at least 8 weeks;

4. Subject has given written informed consent;

5. Subject is able to comply with the protocol (e.g. answer questions, collect urine).

1. Known inflammatory bowel disease (e.g. Crohn's disease);

2. Known lactose intolerance and not using lactase;

3. Known galactosaemia;

4. Known cow's milk allergy;

5. Known major hepatic dysfunction: symptomatic hepatic dysfunction or previous serum transaminase (ALAT, ASAT, or alkaline phosphatase) levels more than 5 times upper limit of normal;

6. Known renal dysfunction: symptomatic renal dysfunction or a previous GFR < 60 mL/min/1.73 m2 for longer than 3 months (stage 3 - stage 5 chronic kidney disease);

7. Requirement of a protein restricted diet (such as for renal failure);

8. Ileostomy or colostomy;

9. Parenteral feeding;

10. Tube feeding;

11. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;

12. Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.